We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences (PACB) Loses 4.1% Post Reporting Q3 Loss
Read MoreHide Full Article
Pacific Biosciences of California, Inc. (PACB - Free Report) declined 4.1% on Nov 3 after the company reported earnings results.
The company reported third-quarter 2020 loss per share of 14 cents, in line with the Zacks Consensus Estimate. The company had reported loss of 19 cents in the year-ago quarter.
Revenues totaled $19.1 million, which missed the Zacks Consensus Estimate by 6.5% and also fell 12.8% from the year-ago quarter’s tally.
Segmental Analysis
Product Revenues: At this segment, revenues amounted to $15.7 million, down 15.1% from the prior-year quarter’s tally.
Service and Other Revenues: At this segment, revenues came in at $3.3 million, down 2.9% year over year.
Margins
Gross profit in the third quarter was $7.1 million, up 2.2% year over year. Gross margin was 37% of total revenues, expanding 547 basis points.
Operating expenses totaled $31.2 million, down 10.8% year over year.
Operating loss came in at $24.2 million, narrower than the year-ago quarter’s loss of $28.1 million.
Pacific Biosciences of California, Inc. Price, Consensus and EPS Surprise
The company exited the third quarter with cash, cash equivalents and investments, excluding restricted cash, of $208.6 million compared with $120 million at the end of the second quarter.
Our Take
Pacific Biosciences ended the third quarter on a weak note. Nonetheless, the company continues to gain from its flagship Sequel system. The launch of the Sequel IIe System and collaboration with Asuragen during the quarter instill optimism.Gross margin expansion was noted in the quarter. Additionally, the company received termination fees from Illumina, which got reflected on the results.
However, Pacific Biosciences saw revenue decline in both its key operating segments.
Zacks Rank and Key Picks
Pacific Biosciences currently carries a Zacks Rank #3 (Hold).
Thermo Fisher reported third-quarter 2020 adjusted EPS of $5.63, beating the Zacks Consensus Estimate by 28.8%. Revenues of $8.52 billion surpassed the consensus mark by 10%.
Align Technology reported third-quarter 2020 adjusted EPS of $2.25, which surpassed the Zacks Consensus Estimate by 281.4%. Revenues of $734.1 million outpaced the consensus mark by 38%.
AngioDynamics reported first-quarter fiscal 2021 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss per share of 6 cents. Revenues of $70.2 million beat the consensus mark by 6.9%.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, SherazMian hand-picks one to have the most explosive upside of all.
With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.
The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Image: Bigstock
Pacific Biosciences (PACB) Loses 4.1% Post Reporting Q3 Loss
Pacific Biosciences of California, Inc. (PACB - Free Report) declined 4.1% on Nov 3 after the company reported earnings results.
The company reported third-quarter 2020 loss per share of 14 cents, in line with the Zacks Consensus Estimate. The company had reported loss of 19 cents in the year-ago quarter.
Revenues totaled $19.1 million, which missed the Zacks Consensus Estimate by 6.5% and also fell 12.8% from the year-ago quarter’s tally.
Segmental Analysis
Product Revenues: At this segment, revenues amounted to $15.7 million, down 15.1% from the prior-year quarter’s tally.
Service and Other Revenues: At this segment, revenues came in at $3.3 million, down 2.9% year over year.
Margins
Gross profit in the third quarter was $7.1 million, up 2.2% year over year. Gross margin was 37% of total revenues, expanding 547 basis points.
Operating expenses totaled $31.2 million, down 10.8% year over year.
Operating loss came in at $24.2 million, narrower than the year-ago quarter’s loss of $28.1 million.
Pacific Biosciences of California, Inc. Price, Consensus and EPS Surprise
Pacific Biosciences of California, Inc. price-consensus-eps-surprise-chart | Pacific Biosciences of California, Inc. Quote
Cash Position
The company exited the third quarter with cash, cash equivalents and investments, excluding restricted cash, of $208.6 million compared with $120 million at the end of the second quarter.
Our Take
Pacific Biosciences ended the third quarter on a weak note. Nonetheless, the company continues to gain from its flagship Sequel system. The launch of the Sequel IIe System and collaboration with Asuragen during the quarter instill optimism.Gross margin expansion was noted in the quarter. Additionally, the company received termination fees from Illumina, which got reflected on the results.
However, Pacific Biosciences saw revenue decline in both its key operating segments.
Zacks Rank and Key Picks
Pacific Biosciences currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced their quarterly results are Thermo Fisher Scientific Inc. (TMO - Free Report) , Align Technology, Inc (ALGN - Free Report) and AngioDynamics, Inc. (ANGO - Free Report) , each carrying a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Thermo Fisher reported third-quarter 2020 adjusted EPS of $5.63, beating the Zacks Consensus Estimate by 28.8%. Revenues of $8.52 billion surpassed the consensus mark by 10%.
Align Technology reported third-quarter 2020 adjusted EPS of $2.25, which surpassed the Zacks Consensus Estimate by 281.4%. Revenues of $734.1 million outpaced the consensus mark by 38%.
AngioDynamics reported first-quarter fiscal 2021 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss per share of 6 cents. Revenues of $70.2 million beat the consensus mark by 6.9%.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, SherazMian hand-picks one to have the most explosive upside of all.
With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.
The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Click Here, See It Free >>